[breadcrumb_custom]

How To Know If Cara Therapeutics Inc (NASDAQ:CARA) Is Expensive At $0.57.

In last trading session, Cara Therapeutics Inc (NASDAQ:CARA) saw 0.45 million shares changing hands with its beta currently measuring 0.56. Company’s recent per share price level of $0.57 trading at $0.05 or 8.79% at ring of the bell on the day assigns it a market valuation of $30.82M. That closing price of CARA’s stock is at a discount of -2000.0% from its 52-week high price of $11.97 and is indicating a premium of 12.28% from its 52-week low price of $0.50. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.5 million shares which gives us an average trading volume of 807.68K if we extend that period to 3-months.

Cara Therapeutics Inc (NASDAQ:CARA) trade information

Upright in the green during last session for gaining 8.79%, in the last five days CARA remained trading in the red while hitting it’s week-highest on Wednesday, 02/07/24 when the stock touched $0.57 price level, adding 5.0% to its value on the day. Cara Therapeutics Inc’s shares saw a change of -23.85% in year-to-date performance and have moved -1.45% in past 5-day. Cara Therapeutics Inc (NASDAQ:CARA) showed a performance of -8.42% in past 30-days. Number of shares sold short was 2.38 million shares which calculate 1.84 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Cara Therapeutics Inc (CARA) estimates and forecasts

Statistics highlight that Cara Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -81.69% of value to its shares in past 6 months, showing an annual growth rate of -37.11% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to increase by 26.80% in the current quarter and calculating 14.30% increase in the next quarter. This year revenue growth is estimated to fall -34.50% from the last financial year’s standing.

5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $9.42 million for the same. And 5 analysts are in estimates of company making revenue of $2.26 million in the next quarter that will end on Mar 2024. Company posted $3.26 million and $6.17 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 188.90% while estimating it to be -63.30% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 3.05% during past 5 years.

CARA Dividends

Cara Therapeutics Inc is more likely to be releasing its next quarterly report between March 04 and March 08 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Cara Therapeutics Inc (NASDAQ:CARA)’s Major holders

Insiders are in possession of 14.68% of company’s total shares while institution are holding 48.68 percent of that, with stock having share float percentage of 57.06%. Investors also watch the number of corporate investors in a company very closely, which is 48.68% institutions for Cara Therapeutics Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at CARA for having 3.7 million shares of worth $10.48 million. And as of Jun 29, 2023, it was holding 6.85% of the company’s outstanding shares.

The second largest institutional holder is Vanguard Group Inc, which was holding about 2.59 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 4.80% of outstanding shares, having a total worth of $7.34 million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 1.35 million shares of worth $3.83 million or 2.50% of the total outstanding shares. The later fund manager was in possession of 1.12 million shares on Aug 30, 2023, making its stake of worth around $2.87 million in the company or a holder of 2.06% of company’s stock.

On Key

Related Posts